These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14571680)

  • 1. [The use of pronoran (piribedil) in Parkinson's disease].
    Fedorova NV; Artem'eva EG; Gigir' IP; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(9):71-2. PubMed ID: 14571680
    [No Abstract]   [Full Text] [Related]  

  • 2. [An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):41-7. PubMed ID: 15875942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 6. [The use of piribedil in early and late stages of Parkinson's disease].
    Fedorova NV; Kulua TK; Gubanova ЕN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):96-98. PubMed ID: 26525631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Parkinson's disease: use of piribedil].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):54-6. PubMed ID: 14870695
    [No Abstract]   [Full Text] [Related]  

  • 9. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Action of piribedil in Parkinson disease. Multicenter study].
    Ziégler M; Rondot P
    Presse Med; 1999 Sep; 28(26):1414-8. PubMed ID: 10518963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
    Eggert K; Öhlwein C; Kassubek J; Wolz M; Kupsch A; Ceballos-Baumann A; Ehret R; Polzer U; Klostermann F; Schwarz J; Fuchs G; Jost W; Albert A; Haag A; Hermsen A; Lohmüller K; Kuhn K; Wangemann M; Oertel WH;
    Clin Neuropharmacol; 2014; 37(4):116-22. PubMed ID: 24992083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of Parkinson's disease. Practical criteria of treatment].
    Casacchia M; Carolei A; Zamponi A; Agnoli A; Fazio C
    Recenti Prog Med; 1976 May; 60(5):567-84. PubMed ID: 14360
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
    Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
    Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alpha-2 adrenergic receptors and Parkinson's disease].
    Bonnet AM
    Presse Med; 2002 Jul; 31(25):1193-5. PubMed ID: 12192732
    [No Abstract]   [Full Text] [Related]  

  • 17. The phonological loop in medicated patients with Parkinson's disease: presence of phonological similarity and word length effects.
    Moreaud O; Fournet N; Roulin JL; Naegele B; Pellat J
    J Neurol Neurosurg Psychiatry; 1997 Jun; 62(6):609-11. PubMed ID: 9219747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of pronoran in the therapy of late stage of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(4):34-7. PubMed ID: 16737158
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.